Stockreport

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-Hodgkin lymphoma, and a new Phase II trial for long COVID. Despite bullish long-term outloo [Read more]